Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 33
Filter
1.
Histopathology ; 48(5): 481-504, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16623775

ABSTRACT

Classification and proper treatment of extranodal lymphoma is hindered by the diversity of lymphoma types and the relative rarity of many of these tumour types. In order to review controversial issues in extranodal lymphoma diagnosis, a joint Workshop of the European Haematopathology Association (EAHP) and the Society for Hematopathology (SH) was held, where 99 selected cases were reviewed and discussed. This Workshop summary is focused on the most controversial aspect of cutaneous B-cell lymphoma, other extranodal B-cell lymphomas, plasmablastic lymphoma and anaplastic large-cell lymphoma in extranodal sites, and makes practical recommendations about diagnosis and therapeutic approaches.


Subject(s)
Lymphoma, B-Cell/pathology , Lymphoma, T-Cell/pathology , Diagnosis, Differential , Gastrointestinal Tract/pathology , Humans , Lung/pathology , Lymphoma, B-Cell/classification , Lymphoma, T-Cell/classification , Salivary Glands/pathology , Skin/pathology
2.
Article in English | MEDLINE | ID: mdl-11722988

ABSTRACT

This review covers the diagnosis and management of natural killer and peripheral T-cell lymphomas (PTCL). Problems with PTCL include their rarity, representing usually 10-15% of non-Hodgkin's lymphomas in the Western Hemisphere, morphologic heterogeneity, and lack of immunophenotypic markers for clonality. Additionally, their clinical behavior is variable and may not correlate with morphology. Dr. Kinney gives a general overview of the diagnosis of PTCL and NK cell neoplasms. Emphasis will be placed on extranodal T cell and natural killer (NK) cell lymphomas such as hepatosplenic lymphoma, subcutaneous panniculitis-like lymphoma and nasal/nasal type T/NK-cell lymphoma. The use of ALK gene regulation in the classification of anaplastic large cell lymphoma is also reviewed. Dr. Loughran describes current understanding of the pathogenesis of large granular lymphocyte (LGL) leukemia. The discussion focuses on LGL leukemia as an instructive model of dysregulated apoptosis causing both malignant and autoimmune disease. Current management options and mechanisms of therapeutic response are also described. Dr. Greer addresses whether PTCL should be treated differently from the more common diffuse large B cell lymphomas. He discusses the therapeutic options for anaplastic large cell lymphoma (ALCL), from a conservative approach for primary cutaneous ALCL to combination chemotherapy for the highly chemosensitive ALCL expressing anaplastic lymphoma kinase. He reviews therapy options for the extranodal subtypes of PTCL by drawing from series in adults, pediatrics, dermatology, and the Far East.


Subject(s)
Killer Cells, Natural/pathology , Lymphoma, T-Cell, Peripheral/pathology , Lymphoproliferative Disorders/pathology , Antineoplastic Agents/therapeutic use , Humans , Leukemia, T-Cell/etiology , Leukemia, T-Cell/pathology , Leukemia, T-Cell/therapy , Lymphoma, T-Cell, Peripheral/etiology , Lymphoma, T-Cell, Peripheral/therapy , Lymphoproliferative Disorders/etiology , Lymphoproliferative Disorders/therapy , T-Lymphocytes/pathology
4.
Am J Clin Pathol ; 115(6): 894-8, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11392887

ABSTRACT

Accurate platelet enumeration is critical for optimal treatment of patients with platelet and bleeding disorders, leukemias, and other neoplasias. The majority of automated hematology analyzers count platelets by size differentiation alone, which may result in falsely elevated platelet counts for samples containing interfering particles such as RBC fragments, microcytes, and cell debris. Most analyzers flag questionable platelet counts, necessitating review of results with confirmation by an alternative method, thus increasing the cost of performing platelet counts and delaying results. We studied the effect of a new platelet analysis method, based on measurement of size and refractive index, on the laboratory review rate for platelet counting. We demonstrated that this method yields higher accuracy for platelet counts in samples with interferences, especially for platelet counts less than 50 x 10(3)/microL (< 50 x 10(9)/L). As a result of the 2-dimensional analysis, the review rate for platelet counts was reduced by 65% in our institution, resulting in substantial savings.


Subject(s)
Platelet Count/methods , Blood Platelets/cytology , Cell Size , Costs and Cost Analysis , Humans , Platelet Count/economics , Refractometry , Sensitivity and Specificity
5.
Neurosurgery ; 47(2): 454-6; discussion 456-7, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10942021

ABSTRACT

OBJECTIVE AND IMPORTANCE: A rare case of dura-based primary cerebral Hodgkin's disease clinically and radiographically indistinguishable from a meningioma is described. CLINICAL PRESENTATION: A 55-year-old immunocompetent woman presented with headaches and ataxia. Magnetic resonance images demonstrated a circumscribed diffusely enhancing mass with a dural tail attached to the cerebellar tentorium. INTERVENTION: Operative inspection also suggested a meningioma, but a frozen section of the firm mass revealed an inflammatory lesion. Subsequent pathological analysis demonstrated Hodgkin's disease, nodular sclerosing type. An extensive workup revealed no systemic disease. CONCLUSION: This case illustrates the rare occurrence of primary intracranial Hodgkin's disease and its mimicry of meningioma.


Subject(s)
Brain Neoplasms/diagnosis , Hodgkin Disease/diagnosis , Meningeal Neoplasms/diagnosis , Meningioma/diagnosis , Brain Neoplasms/pathology , Brain Neoplasms/radiotherapy , Brain Neoplasms/surgery , Combined Modality Therapy , Diagnosis, Differential , Female , Hodgkin Disease/pathology , Hodgkin Disease/radiotherapy , Hodgkin Disease/surgery , Humans , Magnetic Resonance Imaging , Middle Aged
6.
Mod Pathol ; 13(12): 1308-14, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11144927

ABSTRACT

Mantle cell lymphoma (MCL) is more aggressive when compared with other lymphomas composed of small, mature B lymphocytes. Cyclin D1 is overexpressed in MCL as a result of the translocation t(11;14)(q13;q32). Cyclin D1 immunohistochemistry in fixed, paraffin-embedded tissue contributes to the precise and reproducible diagnosis of MCL without the requirement of fresh tissue. However, its use in bone marrow biopsies is not well established. In addition, increased levels of cyclin D1 mRNA have been found in hairy cell leukemia but have not consistently been detected by immunohistochemistry. We used a polyclonal antibody and heat-induced antigen retrieval conditions to evaluate 73 fixed, paraffin-embedded bone marrow, spleen, and lymph node specimens with small B-cell infiltrates, obtained from 55 patients. Cyclin D1 was overexpressed in 13/13 specimens of MCL (usually strong, diffuse reactivity in most tumor cells) and in 14/14 specimens of hairy cell leukemia (usually weak, in a subpopulation of tumor cells). No reactivity was detected in five cases of B-chronic lymphocytic leukemia; five cases of splenic marginal zone lymphoma; six cases of nodal marginal zone cell lymphoma; two cases of gastric marginal zone cell lymphoma; or ten benign lymphoid infiltrates in bone marrow, spleen, or lymph nodes. In summary, although the total number of studied cases is small and a larger series of cases may be required to confirm our data, we present optimized immunohistochemical conditions for cyclin D1 in fixed, paraffin-embedded tissue that can be useful in distinguishing MCL and hairy cell leukemia from other small B-cell neoplasms and reactive lymphoid infiltrates.


Subject(s)
Cyclin D1/metabolism , Leukemia, Hairy Cell/metabolism , Lymphoma, Mantle-Cell/metabolism , Humans , Immunohistochemistry , Leukemia, Hairy Cell/pathology , Lymphoma, Mantle-Cell/pathology , Lymphoproliferative Disorders/metabolism , Lymphoproliferative Disorders/pathology
7.
Hum Pathol ; 30(9): 1040-9, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10492038

ABSTRACT

The human myeloid cell nuclear differentiation antigen (MNDA) is a nuclear antigen known to be expressed in mature myelomonocytic cell lines. An extensive immunocytochemical evaluation of fixed tissues confirmed MNDA expression in normal maturing granulocytes and monocytes and in acute nonlymphocytic leukemias and chronic myelogenous leukemia. MNDA was not detected in normal tissue histiocytes but was found in activated macrophages and foreign body giant cells associated with inflammation. Flow cytometric cell sorting of normal bone marrow established that MNDA is initially expressed in myeloid blast cells. Examination of lymphoid tissues showed a low level of expression in a population of normal mande B lymphocytes but not in germinal center cells or plasma cells. A subset of B cell neoplasms expressing MNDA included hairy cell leukemia, parafollicular (monocytoid) B cell lymphoma, mantle cell lymphoma, and small lymphocytic lymphoma. Cell sorting of normal bone marrow showed MNDA expression in CD20+/CD10-/CD5- B cells. MNDA was not detected in other normal bone marrow or all other nonhematopoietic cells. The hematopoietic cell-specific pattern of MNDA expression was elucidated through a comprehensive analysis of normal and neoplastic tissues, and the results provide further evidence of the coexpression of B- and myeloid cell markers in neoplastic B cells and identify a normal B cell population that might be related to the cell of origin of a subset of B cell neoplasms.


Subject(s)
Antigens, Differentiation, Myelomonocytic/metabolism , B-Lymphocytes/metabolism , Bone Marrow Cells/metabolism , Leukemia/metabolism , Lymphoma/metabolism , Transcription Factors/metabolism , Antibody Specificity , Granulocytes/metabolism , Humans , Immunohistochemistry , Inflammation/metabolism , Leukemia, Lymphoid/metabolism , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/metabolism , Leukemia, Myeloid, Acute/metabolism , Lymphoid Tissue/metabolism , Monocytes/metabolism , Tissue Distribution
8.
J Pediatr Surg ; 34(4): 635-8, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10235342

ABSTRACT

PURPOSE: The aim of this study was to determine potential problems in the diagnosis and management of children with pleural effusions and malignant lymphoma as well as the efficacy of thoracentesis. METHODS: The case histories of six children with malignant lymphoma who presented with pleural effusions were reviewed. Thoracentesis was performed using the Seldinger technique. RESULTS: Four of the children presented with symptoms and chest radiograph findings similar to pneumonia. A large mediastinal mass was present in two children. Pleural fluid analysis resulted in a definitive diagnosis of lymphoma in five of the six children. Two of the children had symptoms of reexpansion pulmonary edema after removal of pleural fluid. An empyema developed in one child after thoracotomy and chest tube placement. Reaccumulation of pleural fluid was common before initiating chemotherapy. CONCLUSIONS: Malignant pleural effusions frequently are present in children with non-Hodgkin's lymphoma. They may present with respiratory distress because of the size of the effusion, the mediastinal mass, or both. Management of these pleural effusions is associated with potential complications, some of which are life threatening. Thoracentesis is the initial diagnostic and therapeutic procedure of choice. The use of a Seldinger technique for thoracentesis has proved useful and safe. In patients with large effusions, aggressive removal of the pleural fluid may be followed by reexpansion pulmonary edema.


Subject(s)
Lymphoma, Non-Hodgkin/complications , Pleural Effusion, Malignant/therapy , Adolescent , Chest Tubes , Child , Female , Humans , Male , Pleural Effusion, Malignant/etiology
9.
Hum Pathol ; 30(2): 173-7, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10029445

ABSTRACT

Microsatellite instability (MSI) is a recently described type of genetic alteration resulting from defects in the DNA mismatch repair genes that appears to play an integral role in neoplastic transformation. MSI has been described in a wide variety of malignancies; however, data regarding the role of MSI in the pathogenesis of non-Hodgkin's lymphoma (NHL) are limited. MSI appears to be important in some T-cell lymphomas, including ALCL arising in immunocompromised patients. In addition, MSI has recently been identified in CD30+ cutaneous lymphoproliferative processes and lymphoblastic lymphoma. In this study, we have analyzed five well-characterized cases of systemic T-cell ALCL arising in immunocompetent patients for the presence of MSI. Genomic DNA isolated from paired normal and tumor tissue was analyzed at seven microsatellite loci by polymerase chain reaction. We were unable to identify MSI or loss of heterozygosity (LOH) in our cases, suggesting that abnormalities in the DNA mismatch repair system do not play a major role in the pathogenesis of most systemic ALCL. Our data provide additional molecular evidence that the various subgroups of lymphoma with ALCL morphology are biologically distinct processes.


Subject(s)
Lymphoma, Large-Cell, Anaplastic/genetics , Adolescent , Adult , Aged , Female , Humans , Immunocompetence , Loss of Heterozygosity , Lymphoma, Large-Cell, Anaplastic/pathology , Male , Microsatellite Repeats
10.
Hum Pathol ; 30(2): 228-36, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10029454

ABSTRACT

Anaplastic large cell lymphomas (ALCL) are a heterogeneous group of CD30+ large cell lymphomas; the most characteristic type have a T or null cell phenotype, often express epithelial membrane antigen (EMA) and cytolytic lymphocyte markers, and often possess a nonrandom t(2;5)(p23;q35) chromosomal translocation. We studied 22 (19 T, 1 null, 2 B cell) ALCL, including four primary cutaneous ALCL (PC-ALCL), for the expression of TIA-1, the cytotoxic T lymphocyte (CTL) or natural killer (NK) cell-associated antigens CD4, CD8, betaF1, TCRdelta1, CD56, and CD57, the ALCL-associated antigens p80 and EMA, and the Hodgkin's disease-associated marker CD15 to better define the relationship of these markers to histological subtype, primary site, and patient clinical characteristics. TIA-1 expression was seen in 12 of 20 (60%) T or null cell ALCLs with a cytoplasmic, granular distribution. Ultrastructural studies showed cytotoxic-type granules (dense core, multivesicular, and intermediate types) with TIA-1 localized to granules on immunogold labeling. TIA-1 staining strongly correlated with young patient age (< or = 32 years, P < .05) and EMA expression (P < .05). Excluding the four PC-ALCL cases, TIA-1 staining also correlated with p80 expression (P < .05) in all of the T cell cases. Three CD15+ cases were TIA-1-. TIA-1 expression in T or null cell ALCL was seen in all morphological subtypes (2 of 2 small cell variant, 3 of 4 monomorphic variant, and 7 of 14 pleomorphic variant) and primary tumor sites (6 of 14 nodal, 2 of 4 primary cutaneous, 2 of 2 bone, and 2 of 2 soft tissue). TIA-1+ granules were seen in all subsets: 5 of 6 CD4+, 1 of 2 CD8+, 4 of 8 CD56+, and 1 of 2 CD57+ ALCL. Of note, 4 of 10 T or null cell ALCL expressed gammadelta T-cell receptors (TCR), whereas only 1 of 10 T or null cell ALCL was alphabeta TCR+; TCR were not detected in five cases. TIA-1 was expressed by 3 of 4 gammadelta TCR+ ALCL and 1 of 1 alphabeta TCR+ ALCL. These data support a cytotoxic lymphocyte phenotype in most T or null cell ALCL and suggest that some T cell ALCL are derived from cytolytic CD4+ T cells, gammadelta T cells, or NK-like (CD56+ or CD57+) T cells.


Subject(s)
Antigens, CD/biosynthesis , Lymphoma, Large-Cell, Anaplastic/metabolism , Membrane Proteins/biosynthesis , Proteins , RNA-Binding Proteins/biosynthesis , Receptors, Antigen, T-Cell/biosynthesis , Adolescent , Adult , Aged , Child , Female , Humans , Immunophenotyping , Infant , Lymphoma, Large-Cell, Anaplastic/pathology , Lymphoma, Large-Cell, Anaplastic/ultrastructure , Male , Microscopy, Immunoelectron , Middle Aged , Mucin-1/biosynthesis , Oncogene Proteins, Fusion/biosynthesis , Poly(A)-Binding Proteins , Protein-Tyrosine Kinases/biosynthesis , T-Cell Intracellular Antigen-1
11.
Am J Clin Pathol ; 111(1 Suppl 1): S56-67, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9894470

ABSTRACT

Anaplastic large cell lymphoma (ALCL) is clinically and pathologically heterogeneous, leading to some difficulty in its diagnosis and acceptance as a specific entity. ALCL can be subdivided into different groups according to histologic features (pleomorphic, monomorphic, small cell predominant, Hodgkin's disease-related, and other less common variants), immunophenotype (T, null, B, and rarely B and T), and clinical features (systemic, primary cutaneous type, ALCL arising in HIV-positive patients, and ALCL occurring after another lymphoproliferative process, such as lymphomatoid papulosis, mycosis fungoides, and Hodgkin's disease. Cytogenetic studies and subsequent cloning of the translocation t(2;5) have shown a high degree of association with Ki-1-positive lymphoma but have revealed that this genetic abnormality is not specific for anaplastic morphologic features, is more common in the monomorphic and small cell variants, and is rare in primary cutaneous ALCL. It is likely that this t(2;5)-positive group is pathogenetically related. The purpose of this article is to review the pathologic and clinical spectrum of ALCL, including the borderline with Hodgkin's disease and lymphomatoid papulosis and to discuss the use of the t(2;5) in better defining a more specific molecular pathologic entity within this group of diseases with CD30 expression.


Subject(s)
Lymphoma, Large-Cell, Anaplastic/pathology , Anaplastic Lymphoma Kinase , Chromosomes, Human, Pair 2 , Chromosomes, Human, Pair 5 , Humans , Immunophenotyping , Lymphoma, Large-Cell, Anaplastic/genetics , Lymphoma, Large-Cell, Anaplastic/immunology , Protein-Tyrosine Kinases , Receptor Protein-Tyrosine Kinases , Translocation, Genetic
12.
Am J Clin Pathol ; 111(1 Suppl 1): S104-18, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9894475

ABSTRACT

Excluding mycosis fungoides, almost one third of T-cell lymphomas arise as primary tumors in extranodal sites, and these lymphomas are biologically different from their nodal counterparts. The revised European-American classification of lymphoid neoplasms and the World Health Organization classification have emphasized the importance of site in defining T-cell neoplasms and have included such new categories as hepatosplenic gamma delta T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, nasal and nasal-type T-cell lymphoma, enteropathy-type intestinal T-cell lymphoma, and primary cutaneous anaplastic large cell lymphoma. Although site is important, different lymphomas may occur at a particular location, and multiple parameters are required to define each type precisely. Cytologic features usually are not specific, and there are no morphologic correlates, such as follicular nodulation or plasmacytic differentiation in the B-cell system, to help define T-cell neoplasms. The T-cell system is biologically complex, consisting of populations with alpha beta and gamma delta receptors and helper and suppressor/cytotoxic phenotypes. In addition, NK cells resemble T cells in antigen expression, function, and patterns of disease, adding to the difficulty in defining T-cell and NK-cell neoplasms. Therefore, a complete workup with a combination of clinical, immunophenotypic, cytogenetic, and molecular genetic studies often is necessary to characterize these neoplasms. The role of each of these parameters in the diagnosis of T-cell and NK-cell neoplasms is discussed.


Subject(s)
Killer Cells, Natural/pathology , Lymphoma, T-Cell/classification , Lymphoma, T-Cell/pathology , Antigens, CD , Diagnosis, Differential , Genotype , Humans , Immunophenotyping , Lymphoma, T-Cell/genetics , Lymphoma, T-Cell/immunology
13.
Am J Surg Pathol ; 23(1): 49-58, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9888703

ABSTRACT

The disease spectrum of anaplastic large cell lymphoma (ALCL) includes a biologically aggressive small cell variant (SCV). The SCV may progress to ALCL, but little is known about the transformation process and its significance. The goals of this study were (1) to identify the clinical and pathologic features that characterize ALCL arising in SCV and (2) to determine whether some cases with ALCL histologic appearance at the outset arose from an SCV. Seventeen SCV were reviewed, and four cases (24%) transformed to ALCL as shown by subsequent biopsy. The ALCLs were predominantly monomorphic (3 cases) rather than pleomorphic (1 case). Residual SCV was detected at transformation in 3 of 4 cases. Twenty-one de novo T-cell ALCLs were reviewed for an SCV component; such a component was identified in two ALCLs with monomorphic features, suggesting a preceding SCV phase. There was no change in the immunophenotype between the SCV and ALCL, all marking as EMA+ T cells. Expression of p80 was detected in 3 of 4 (75%) SCV with transformation and 10 of 12 (77%) SCV without transformation. Chromosomal abnormalities involving the sex chromosomes and 6, 7, 9, and 15, in addition to the characteristic t(2;5)(p23;q35), were present in 2 cases at transformation. Times to transformation ranged from 1 to 146 months (mean: 63 months) after diagnosis. Transformation to ALCL signaled a rapid clinical course, with 75% of patients dying in less than a year; one patient remains alive at 15 months. In summary, some ALCLs, particularly those with monomorphic features, arise from an SCV. Transformation to ALCL signals a rapid course, with death occurring in less than a year in most cases. Necrosis in the SCV may be predictive of transformation. Chromosomal abnormalities in addition to the t(2;5)(p23;q35) are present at transformation, suggesting that multiple genetic alterations are involved in disease progression.


Subject(s)
Cell Transformation, Neoplastic/pathology , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Lymphoma, Large-Cell, Anaplastic/pathology , Lymphoma, T-Cell/pathology , Adolescent , Adult , Antibodies, Monoclonal , Antigens, Neoplasm/analysis , Child, Preschool , Chromosome Aberrations/pathology , Chromosome Disorders , Cytogenetics , Female , Humans , Immunoenzyme Techniques , Immunophenotyping , Leukemia, Lymphocytic, Chronic, B-Cell/chemistry , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Lymphoma, Large-Cell, Anaplastic/chemistry , Lymphoma, Large-Cell, Anaplastic/genetics , Lymphoma, T-Cell/chemistry , Lymphoma, T-Cell/genetics , Male
14.
Mod Pathol ; 11(3): 239-46, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9521469

ABSTRACT

Microvillous lymphomas (MVLs) are rare, poorly defined, large transformed cell lymphomas characterized by a cohesive sinus growth pattern and ultrastructural cytoplasmic processes. Most MVLs express B-cell antigens and have been compared ultrastructurally to transformed follicular center cells and follicular dendritic cells. For additional definition of the immunophenotype of these unusual B-cell lymphomas, we evaluated eight cases of MVL for B-cell-associated antigens (CD21, CD35, CDw75, DBA.44, bcl-2) using paraffin immunoperoxidase. CD56, the neural cell adhesion molecule, was tested because of the unusual, cohesive, sinus pattern of tumor cell growth seen in MVL. Molecular analysis for immunoglobulin heavy chain and bcl-2 gene rearrangements was performed to confirm B-cell clonality and to evaluate cases for possible follicular origin. All of the cases were marked as B cells (CD20 positive), and the clonal nature confirmed by immunoperoxidase in five cases (63%) of eight and polymerase chain reaction for immunoglobulin heavy chain in seven cases (88%) of eight. CDw75 staining was present in six cases and CD74 in seven. DBA.44 and CD21 and CD35 were negative in all of the cases, and four cases (50%) of eight expressed CD56. bcl-2 protein expression was seen in seven of eight cases; bcl-2 gene rearrangement was present in one case (33%) of three studied. In conclusion, MVLs are B-cell lymphomas demonstrating clonal immunoglobulin heavy chain gene rearrangement. The neoplastic cells express CDw75 and bcl-2 protein. The presence of bcl-2 rearrangements in a limited number of cases implies that at least some MVLs have a follicular origin. Fifty percent of MVLs express CD56, suggesting a role for adhesion molecules in the distribution of this lymphoma.


Subject(s)
CD56 Antigen/analysis , Lymphoma, B-Cell/pathology , Lymphoma, Large B-Cell, Diffuse/pathology , Microvilli/pathology , Aged , Antigens, CD/analysis , Antigens, CD20/analysis , Biomarkers, Tumor/analysis , Biomarkers, Tumor/immunology , Biopsy , CD56 Antigen/genetics , Cell Transformation, Neoplastic/chemistry , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/immunology , Chromosomes, Human, Pair 7/genetics , Cystic Fibrosis Transmembrane Conductance Regulator/analysis , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , DNA, Neoplasm/analysis , DNA, Neoplasm/genetics , DNA, Neoplasm/isolation & purification , Female , Gene Amplification , Gene Expression/genetics , Gene Expression/immunology , Gene Rearrangement, B-Lymphocyte, Heavy Chain , Humans , Immunohistochemistry , Immunophenotyping , Ki-1 Antigen/analysis , Lymphocyte Activation/genetics , Lymphocyte Activation/immunology , Lymphoma, B-Cell/chemistry , Lymphoma, B-Cell/ultrastructure , Lymphoma, Large B-Cell, Diffuse/chemistry , Lymphoma, Large B-Cell, Diffuse/genetics , Male , Microvilli/chemistry , Middle Aged , Polymerase Chain Reaction , Proto-Oncogene Proteins c-bcl-2/analysis , Proto-Oncogene Proteins c-bcl-2/genetics , Receptors, Complement 3b/analysis , Receptors, Complement 3d/analysis , Sialyltransferases
15.
Exp Hematol ; 25(11): 1111-7, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9328447

ABSTRACT

The myeloid cell nuclear differentiation antigen (MNDA) is a nuclear protein expressed specifically in developing cells of the human myelomonocytic lineage, including the end-stage monocytes/macrophages and granulocytes. Nuclear localization, lineage- and stage-specific expression, association with chromatin, and regulation by interferon alpha indicate that this protein is involved in regulating gene expression uniquely associated with the differentiation process and/or function of the monocyte/macrophage. MNDA does not bind specific DNA sequences, but rather a set of nuclear proteins that includes nucleolin (C23). Both in vitro binding assays and co-immunoprecipitation were used to demonstrate that MNDA also binds protein B23 (nucleophosmin/NPM). Three reciprocal chromosome translocations found in certain cases of leukemia/lymphoma involve fusions with the NPM/B23 gene, t(5;17) NPM-RARalpha, t(2;5) NPM-ALK, and the t(3;5) NPM-MLF1. In the current study, MNDA was not able to bind the NPM-ALK chimera originating from the t(2;5) and containing residues 1-117 of NPM. However, MNDA did bind the NPM-MLF1 product of the t(3;5) that contains the N-terminal 175 residues of NPM. The additional 58 amino acids (amino acids 117-175) of the NPM sequence that are contained in the product of the NPM-MLF1 fusion gene relative to the product of the NPM-ALK fusion appear responsible for MNDA binding. This additional NPM sequence contains a nuclear localization signal and clusters of acidic residues believed to bind nuclear localization signals of other proteins. Whereas NPM and nucleolin are primarily localized within the nucleolus, MNDA is distributed throughout the nucleus including the nucleolus, suggesting that additional interactions define overall MNDA localization.


Subject(s)
Antigens, Differentiation, Myelomonocytic/metabolism , Leukemia, Myeloid/genetics , Myelodysplastic Syndromes/genetics , Nuclear Proteins/genetics , Proteins/genetics , Recombinant Fusion Proteins/metabolism , Transcription Factors/metabolism , Translocation, Genetic , Acute Disease , Cell Cycle Proteins , Chromosome Mapping , Chromosomes, Human, Pair 2 , Chromosomes, Human, Pair 3 , Chromosomes, Human, Pair 5 , DNA-Binding Proteins , Humans , Nuclear Proteins/biosynthesis , Nucleophosmin , Protein Biosynthesis , Protein-Tyrosine Kinases/biosynthesis , Protein-Tyrosine Kinases/genetics , Recombinant Fusion Proteins/genetics , Tumor Cells, Cultured
16.
Arch Pathol Lab Med ; 121(8): 869-73, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9278617

ABSTRACT

OBJECTIVE: Owing to the increasing number of patients with acquired immunodeficiency syndrome and immunosuppressed transplant patients, disseminated Toxoplasma gondii has emerged as a potentially fatal pathogen. Common presentations include encephalitis, pneumonia, and myocarditis. The objective of this report is to describe the clinical course, histologic features, and outcome in two immunocompromised patients with disseminated toxoplasmosis presenting with parasitemia and panniculitis. MATERIALS AND METHODS: Two cases of disseminated toxoplasmosis presenting with parasitemia (patient 1) and panniculitis (patient 2) were retrieved from the clinical, surgical, and autopsy pathology archives of Vanderbilt University Medical Center, Nashville, Tenn. The histology and diagnostic approaches used are reported. Charts were reviewed for primary diagnosis, therapy protocols, clinical presentation of infection, and outcome. RESULTS: Patient 1 developed a clinically unexplained sepsis syndrome shortly after heart transplantation; T gondii parasitemia was diagnosed by examination of peripheral blood smears. The diagnosis was confirmed at autopsy. Patient 2 was a child undergoing induction chemotherapy for lymphoma who developed rapidly progressive neurologic deterioration accompanied by a maculopapular skin rash; T gondii panniculitis was diagnosed retrospectively when histologic examination was combined with immunohistochemistry. Autopsies performed in both cases confirmed widely disseminated infection. CONCLUSIONS: Disseminated toxoplasmosis should be considered in the differential diagnosis of immunocompromised patients with culture-negative sepsis syndrome, particularly if combined with neurologic, respiratory, or unexplained skin lesions. Examination of Wright's-stained peripheral blood smears or antitoxoplasma immunoperoxidase studies of skin biopsies may be diagnostic and allow rapid initiation of antibiotic therapy. Autopsy findings contributed to both of our cases by documenting the wide-spread heavy parasite burden and demonstrating numerous diagnostic T gondii cyst forms.


Subject(s)
Immunocompromised Host , Toxoplasma/isolation & purification , Toxoplasmosis/pathology , Animals , Child , Fatal Outcome , Female , Humans , Immunohistochemistry , Lung/parasitology , Lung/pathology , Male , Middle Aged , Neutrophils/parasitology , Neutrophils/pathology , Skin/immunology , Skin/parasitology , Skin/pathology , Systemic Inflammatory Response Syndrome/parasitology , Systemic Inflammatory Response Syndrome/pathology , Toxoplasma/immunology , Toxoplasma/ultrastructure
17.
Am J Pathol ; 150(6): 1893-900, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9176382

ABSTRACT

TIA-I is a 15-kd cytotoxic granule-associated protein expressed in natural killer (NK) cells and cytotoxic T lymphocytes. TIA-1 expression was evaluated by paraffin immunohistochemistry in 115 T- or NK-cell neoplasms, 45 B-cell neoplasms, and 45 Hodgkin's lymphomas. TIA-1-positive granules were identified within the cytoplasm of neoplastic cells in 6/6 large granular lymphocytic leukemias, 11/11 hepatosplenic T-cell lymphomas, 15/15 intestinal T-cell lymphomas, 6/6 NK-like T-cell lymphomas of no special type, 2/2 NK-cell lymphomas, 8/9 nasal T/NK-cell lymphomas, 7/8 subcutaneous T-cell lymphomas, 4/5 pulmonary T- or NK-cell angiocentric lymphomas (lymphomatoid granulomatosis), 12/19 T-cell anaplastic large-cell lymphomas, 2/12 nodal peripheral T-cell lymphomas, 1/3 CD8+ cutaneous T-cell lymphomas, and 5/38 classical Hodgkin's disease. All B-cell neoplasms, nodular lymphocyte-predominant Hodgkin's disease (7 cases), CD4+ cutaneous T-cell lymphomas (6 cases), adult T-cell leukemia/lymphomas (3 cases), T-cell chronic or prolymphocytic leukemias (3 cases), and T-cell lymphoblastic leukemia/lymphomas (7-cases) were TIA-1 negative. These findings indicate that most large granular lymphocytic leukemias, hepatosplenic T-cell lymphomas, intestinal T-cell lymphomas, NK-like T-cell lymphomas, NK-cell lymphomas, nasal T/NK-cell lymphomas, subcutaneous T-cell lymphomas, pulmonary angiocentric lymphomas of T or NK phenotype, and anaplastic large-cell lymphomas are cytotoxic T-or NK-cell neoplasms.


Subject(s)
Killer Cells, Natural/metabolism , Leukemia/metabolism , Leukemia/pathology , Lymphoma/metabolism , Lymphoma/pathology , Membrane Proteins/metabolism , Proteins , RNA-Binding Proteins/metabolism , T-Lymphocyte Subsets/metabolism , T-Lymphocytes, Cytotoxic/metabolism , Biopsy , Hodgkin Disease/metabolism , Humans , Immunohistochemistry , Leukemia, B-Cell/metabolism , Leukemia, T-Cell/metabolism , Lymphoma, B-Cell/metabolism , Lymphoma, T-Cell/metabolism , Poly(A)-Binding Proteins , T-Cell Intracellular Antigen-1
18.
J Cell Biochem ; 65(2): 231-44, 1997 May.
Article in English | MEDLINE | ID: mdl-9136080

ABSTRACT

The human myeloid nuclear differentiation antigen (MNDA) is expressed specifically in maturing cells of the myelomonocytic lineage and in monocytes and granulocytes. Epitope enhancement was used to confirm the strict lineage- and stage-specific expression of MNDA in bone marrow as well as in other paraffin-embedded fixed tissues. A 1-kb region of the gene that includes 5' flanking sequence was reported earlier to contain functional promoter activity and was specifically demethylated in expressing cells in contrast to null cells. Further analysis has revealed that this 1-kb fragment promotes higher reporter gene activity in MNDA-expressing cells than non-expressing cells, indicating cell-specific differences in transactivation. This sequence contains consensus elements consistent with myeloid-specific gene expression, including a PU.1 consensus site near the major transcription start site and a cluster of c-Myb sites located several hundred bases upstream of this region. However, analysis of deletion mutants localized nearly all of the promoter activity to a short region (-73 to -16) that did not include the cluster of c-Myb sites. A 4-bp mutation of the core Sp1 consensus element (GC box) (-20) reduced overall promoter activity of the 1-kb fragment. Mutation of the PU.1 site did not significantly affect promoter activity. Only a small region (-35 to +22) including the Sp1 element and transcription start site, but not the PU.1 site was footprinted. The 4-bp mutation of the core Sp1 consensus element abolished footprinting at the site and an antibody super-shift reaction showed that Sp1 is one of the factors binding the consensus site. The Sp1 site also co-localizes with a DNase I hypersensitive site. The results indicate that DNA methylation, chromatin structure, and transactivation at an Sp1 site contribute to the highly restricted expression of this myelomonocytic lineage specific gene.


Subject(s)
Antigens, Differentiation, Myelomonocytic/genetics , Gene Expression , Promoter Regions, Genetic , Proto-Oncogene Proteins/metabolism , Sp1 Transcription Factor/metabolism , Trans-Activators/metabolism , Transcription Factors/genetics , Antigens, Differentiation, Myelomonocytic/analysis , Binding Sites , DNA/metabolism , DNA Footprinting , Deoxyribonuclease I/metabolism , Granulocytes/immunology , Humans , Immunoenzyme Techniques , Monocytes/immunology , Mutagenesis, Site-Directed , Proto-Oncogene Proteins c-myb , Transcription Factors/analysis , Tumor Cells, Cultured
19.
J Am Acad Dermatol ; 35(6): 935-45, 1996 Dec.
Article in English | MEDLINE | ID: mdl-8959953

ABSTRACT

BACKGROUND: Few studies have assessed the long-term outcome of patients with cutaneous T-cell lymphoma (CTCL) treated with extracorporeal photochemotherapy (ECP). OBJECTIVE: Our objective was to assess the efficacy, safety, and survival of a cohort of patients with refractory T-cell lymphoma in various stages of cutaneous involvement who were treated with ECP. METHODS: Twenty patients who had received at least 6 months of ECP between September 1988 and April 1991 were reevaluated and the data analyzed statistically to obtain outcome data through December 1995. RESULTS: A complete response (disappearance of all lesions) was obtained in five patients (25%) and a partial response (disappearance of at least 50% of lesions) in five patients (25%). Of the 10 responders, seven (70%) were weaned from ECP. Two of seven patients had a relapse. Ten patients (50%) showed no response to ECP. No statistically significant differences between responders and nonresponders were found with respect to demographic, clinical, or laboratory variables. Seven patients died of causes directly related to CTCL and two patients died of unrelated causes. Median survival time for the entire cohort was 96 months (range, 16 to 152 months). An assessment of early response after 6 to 8 months of ECP had a sensitivity of 100% and a specificity of 90% for predicting long-term (> 4 years) outcome. Adverse effects were minimal. CONCLUSION: ECP is a safe effective alternative therapy for CTCL that is refractory to other therapies; it can induce a long-term, disease-free remission in a minority of patients. Response in the first 6 to 8 months of treatment predicts long-term outcome.


Subject(s)
Lymphoma, T-Cell, Cutaneous/drug therapy , Photopheresis , Skin Neoplasms/drug therapy , Adult , Aged , Aged, 80 and over , Female , Follow-Up Studies , Humans , Lymphoma, T-Cell, Cutaneous/mortality , Male , Methoxsalen/adverse effects , Methoxsalen/therapeutic use , Middle Aged , Photopheresis/adverse effects , Photosensitizing Agents/adverse effects , Photosensitizing Agents/therapeutic use , Skin Neoplasms/mortality , Survival Rate
20.
Blood ; 87(8): 3437-41, 1996 Apr 15.
Article in English | MEDLINE | ID: mdl-8605362

ABSTRACT

Primary cutaneous CD30+ lymphoproliferative disorders (LPDs), including lymphomatoid papulosis (LyP), anaplastic and nonanaplastic CD30+ large-cell lymphoma, and borderline cases, comprise a clinical and histologic spectrum. Primary cutaneous and primary nodal CD30+ anaplastic large-cell lymphomas (ALCLs) are distinct clinical entities that have identical morphologic features but differ in age of onset, immunophenotype, and prognosis. It can be difficult to distinguish primary cutaneous from nodal ALCLs that secondarily involve the skin, which is important because these diseases differ significantly in response to treatment and clinical outcome. The t(2;5) chromosomal translocation is highly associated with primary CD30+ ALCL of nodal origin. The possible occurrence of t(2;5) in primary cutaneous CD30+ LPDs has not been studied extensively, and it remains to be determined if expression of this translocation can be used to distinguish primary cutaneous ALCL from nodal ALCL that secondarily involves the skin. To address these issues, we studied 43 cases of cutaneous and nodal CD30+ LPDs using reverse transcriptase-polymerase chain reaction (RT-PCR) and/or immunohistochemistry. We found no evidence for the t(2; 5) translocation in 14 cases of primary cutaneous CD30+ LPDs, which included 10 cases of LyP, three cases of primary cutaneous CD30+ ALCL, and one borderline case. These findings were in marked contrast to CD30+ ALCL of nodal origin, in which 19 of 29 (66%) cases were positive for t(2;5), including all five cases with secondary skin involvement. Our results support the hypothesis that (1) primary cutaneous CD30+ LPDs (including LyP) and primary nodal ALCL are distinct diseases that differ in clinical behavior and pathogenesis and (2) differential expression of t(2;5) can help to distinguish between primary cutaneous CD30+ LPDs and ALCL of nodal origin.


Subject(s)
Antigens, Neoplasm , Chromosomes, Human, Pair 2/ultrastructure , Chromosomes, Human, Pair 5/ultrastructure , Ki-1 Antigen , Lymph Nodes/pathology , Lymphoma, Large B-Cell, Diffuse/genetics , Lymphoproliferative Disorders/genetics , Skin Diseases/genetics , Translocation, Genetic , Adult , Base Sequence , Child , Chromosomes, Human, Pair 2/genetics , Chromosomes, Human, Pair 5/genetics , Diagnosis, Differential , Hodgkin Disease/genetics , Hodgkin Disease/pathology , Humans , Hyperplasia , Lymphoma, Large B-Cell, Diffuse/diagnosis , Lymphoma, Large B-Cell, Diffuse/pathology , Lymphomatoid Papulosis/genetics , Lymphomatoid Papulosis/pathology , Lymphoproliferative Disorders/diagnosis , Lymphoproliferative Disorders/pathology , Molecular Sequence Data , Mycosis Fungoides/genetics , Mycosis Fungoides/pathology , Prognosis , RNA, Neoplasm/genetics , Skin Diseases/diagnosis , Skin Diseases/pathology , Skin Neoplasms/diagnosis , Skin Neoplasms/genetics , Skin Neoplasms/pathology , Skin Neoplasms/secondary
SELECTION OF CITATIONS
SEARCH DETAIL
...